Haemonetics Corp
NYSE:HAE
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
US |
Haemonetics Corp
NYSE:HAE
|
4.4B USD | 4.6 | ||
CH |
Alcon AG
SIX:ALC
|
39.6B CHF | 2.1 | ||
JP |
Hoya Corp
TSE:7741
|
6.5T JPY | 7.4 | ||
DK |
Coloplast A/S
CSE:COLO B
|
185.9B DKK | 11.5 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
19B USD | 5.1 | ||
US |
Cooper Companies Inc
NYSE:COO
|
18.1B USD | 2.3 | ||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
59.5B CNY | 7.9 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.1B GBP | 3.8 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.6T KRW | 13.6 | |
CH |
Ypsomed Holding AG
SIX:YPSN
|
5.3B CHF | 9.2 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.6B USD | 1.7 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.